Asia Pathogenomics Japan Co., Ltd.
Business Characteristics
Quick identification of even rare pathogens, contributing to rapid diagnoses in clinical settings
TFDA-certified mNGS platform capable of detecting tens of thousands of pathogen types in a single test
With mNGS technology certified by the TFDA, it can detect more than 27,000 types of pathogens in a single test
Rapid diagnosis and precision medical support for overcoming unknown infectious diseases
Capable of detecting unknown pathogens without setting targets, providing diagnostic reports within 24 to 48 hours
Case Studies
Introduction of APGseq-Basic (mNGS) in medical institutions
While conventional culture tests have a detection rate of approximately 30%, metagenomic NGS allows for the simultaneous detection of tens of thousands of pathogens.
62% improvement in positive detection rate, enhancing diagnostic accuracy by providing diagnostic reports within 24–48 hours.
Collaborating with medical institutions to build a Taiwanese pathogen database.
The pathogen data centered on Europe and the United States had limitations in consistency and accuracy, but the gene analysis database specialized for the Taiwan region has improved identification accuracy and clinical relevance.
Enables diagnostic support tailored to clinical settings and supports regional characteristics.
Company Information
| Company Name | APG Asia Pathogenomics Japan | ||
|---|---|---|---|
| Industry Classification | Manufacturing / Genome analysis | ||
| Headquarters | New Taipei City, Taiwan / Asia Pathogenomics Co., Ltd. | ||
| Year of Establishment | April 2025 | Number of Employees | 1 |
| Capital | 50 million yen | ||
| Main Business Activities | Infection pathogen testing based on next-generation sequencing (metagenomic) | ||
| Business Partners / Key Customers | Medical institutions such as hospitals | ||
| State of Overseas Expansion | Japan | ||
| Funding History | TCI GENE Inc.; Creative Life Science Co., Ltd.; BIOTOOLS Co. Ltd.; SinoPac Securities | ||
| Website | https://www.asiapathogenomics.co.jp/ | ||
Business Expansion Structure in Japan
| Presence of a Japan Branch | Yes | Japanese Language Support | English |
|---|---|---|---|
| Status of Discussion in Japan | April 2025: Established a Japanese corporation. Preparing to provide APGseq®. | ||
| Other |
– Invite Japanese medical experts as advisors to begin collaboration – Discussions have already been conducted with the Ministry of Health, Labour and Welfare and regulatory experts to facilitate approval and ensure the rapid provision of services. – They have reached out to the top three pathogen testing companies in the country and are currently in discussions with companies regarding channel partnerships. |
||
Interviews
Overseas startups expanding into Tokyo
×
Tokyo companies
3-8-3 Marunouchi, Chiyoda-ku, Tokyo
Tokyo Innovation Base 2F
Event space (ROOM)
